Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Expanded Access
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
Home
Next Post
Previous Post
test
September 30, 2023
/
Uncategorized
1
Like
Share
the Post
About
the Author
Related
Posts
Phase 2, multicenter, open-label basket trial of
nab
-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in
TSC1
or
TSC2
genes (PRECISION I)
Aadi Bioscience Announces Preliminary Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 and TSC2 Alterations from a Multi-Institution Expanded Access Study to be Presented at ASCO 2021 Virtual Meeting
ABI-009 (
nab
-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors
Phase 2, Multicenter Open-label Basket Trial of
nab
-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in
TSC1
or
TSC2
(PRECISION I)
Read More
Anupam Dalal, MD
Read More
Andrew Kwon, PhD
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.